Liver disease is currently one of the leading causes of death among people living with HIV. Although platelets alterations are well recognized in the course of liver disease, the impact of thrombocytopenia (TCP: platelet counts <150,000 per microliter), which is highly prevalent among Hazardous Alcohol Users (HAU), is unclear. This lack of information limits the possibility to identify those at risk and to create targeted interventions.
Thrombocytopenia (TCP), a platelet count of less than 150,000 per microliter, is a common hematological complication which affects a sizable proportion of the people living with HIV (PLWH). For many years it was expected that the introduction of Highly Active Antiretroviral Therapy (HAART) would eliminate this problem. However, since its causes are multifactorial, TCP is still present in approximately 15% of the people receiving HAART. In addition to direct destruction caused by the virus, alcohol might be an important contributing factor to TCP persistence. Since TCP is often asymptomatic, clinicians’ only concern has been the risk of bleeding.